Cotinga Pharmaceuticals Inc COTQF

Healthcare Biotechnology

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

GREY:COTQF - Post by User

Cotinga Pharmaceuticals Inc

Bullboard Posts

Post by attila9on Jun 08, 2004 3:50pm

202 Views

Post# 7586906

Here we r at

The end of another trading day & TOM still has not been able to announce any news.And this is a man you trust with your money??He is about as creditable as a politician.IMHO

Bullboard Posts

BMO evolves InvestorLine with enhanced tools for options trading